...
首页> 外文期刊>Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis >Prevalence of IVS10nt-18G/A in Calabrian patients with moderate/mild hemophilia A and relation with Factor VIII inhibitor antibodies
【24h】

Prevalence of IVS10nt-18G/A in Calabrian patients with moderate/mild hemophilia A and relation with Factor VIII inhibitor antibodies

机译:卡拉布里亚中度/轻度血友病患者的IVS10nt-18G / A患病率及其与VIII因子抑制剂抗体的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Hemophilia A is an X-linked bleeding disorder caused by widespread mutations in the factor VIII gene. In the course of a screening to research some hemophilia A mutations, our team has identified and posted a previously unreported nucleotide change in intron 10 in 20 patients with hemophilia A. We tried to identify a possible blood relationship between the people with this mutation, performing a backwards study of every family tree. First, we interviewed the patients and, if possible, parents and grandparents. When direct memory was no longer available, we consulted Registries of Births, Marriages and Deaths, and if these data were not sufficient, going backwards in time, we consulted registries of parish churches where newborns were baptized. The studied mutation was present in 33 hemophilic patients living in Calabria, 28 of them related. Three patients, carriers of this mutation, developed an FVIII inhibitor. In all the cases, the inhibitor development followed intensive treatments, after many days of exposure. Our study displayed the presence of a responsible moderate hemophilia A mutation, limited apparently to our country, probably because of a single ancestral event, and connected with FVIII inhibitor development. Copyright (c) 2015 Wolters Kluwer Health, Inc. All rights reserved.
机译:A型血友病是由VIII因子基因的广泛突变引起的X连锁出血性疾病。在筛选研究某些血友病A突变的过程中,我们的团队已经鉴定并发布了20位血友病A患者中以前未报告的内含子10核苷酸变化。我们试图确定具有这种突变的人之间可能存在的血缘关系,对每个家谱的反向研究。首先,我们采访了患者,如果可能,还采访了父母和祖父母。当不再有直接的记忆时,我们咨询了出生,婚姻和死亡登记处,如果这些数据不足,随着时间的流逝,我们咨询了受洗新生儿的教区教堂的登记处。研究的突变存在于居住在卡拉布里亚的33名血友病患者中,其中28名与之相关。三名患者,此突变的携带者,开发了FVIII抑制剂。在所有情况下,经过数天的暴露后,抑制剂的开发都经过强化治疗。我们的研究表明存在一个负责任的中度血友病A突变,这种突变显然仅限于我们国家,可能是由于单个祖先事件,并且与FVIII抑制剂的发展有关。版权所有(c)2015 Wolters Kluwer Health,Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号